October 25, 2017

Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

News

Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more

May 22, 2017

Betalutin Trial for Non-Hodgkin’s Lymphoma Patients Opens New Expansion Cohort

News

The LYMRIT 37-01 Phase 1/2 trial assessing Betalutin in non-Hodgkin’s lymphoma patients will continue to evaluate Betalutin administered after pre-dosing with lilotomab in a Phase 2 expansion cohort of Arm 4. The ... Read more